Last reviewed · How we verify
NCT06045481
Postexposure Prophylaxis With Single Dose Doxycycline for the Prevention of Tick-borne Relapsing Fever
NA trial testing administration of single dose of doxycycline in Relapsing Fever, Tick-Borne in 526 participants. Not yet recruiting.
31 October 2026
Quick facts
| Lead sponsor | Medical Corps, Israel Defense Force |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 526 |
| Start date | 1 August 2024 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 October 2027 |
Drugs / interventions tested
- administration of single dose of doxycycline — full drug profile →
Conditions studied
- Relapsing Fever, Tick-Borne — all drugs for Relapsing Fever, Tick-Borne →
Sponsor
Medical Corps, Israel Defense Force — full company profile →
Who can join
Adults 18 to 30, any sex, with Relapsing Fever, Tick-Borne. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to compare standard treatment (5 days of doxycycline) vs single dose doxycycline for the prevention of tick-borne relapsing fever in soldiers who found bite marks on their bodies after an activity that includes contact with the ground or staying at a site suspected of being infected with ticks. The main question\[s\] it aims to answer are: * Testing whether preventive treatment with a single dose of doxylin at a dose of 200 mg is effective in preventing recurrent fever, and if so, at what rate * Checking the profile and rate of side effects in each one of the proposed treatment protocols Participants will be treated with standard treatment (5 days of doxycycline) or single dose doxycycline.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06045481
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Medical Corps, Israel Defense Force trials
Trials by the same sponsor.
- NCT07473362 — Hyperbaric Oxygen Therapy for Post Traumatic Stress Disorder - a Pragmatic, Double Blinded Randomized Trial · NA · recruiting
- NCT06123104 — Assessment of Automatic Tourniquets for Soldiers During Wartime · NA · unknown
- NCT04482998 — Efficacy of Various Treatments for Acute Acoustic Trauma. · unknown
- NCT04482985 — Meclizine Plasma Levels in Responders and Non-responders · Phase 4 · unknown
- NCT05657340 — Video Head Impulse Test and Seasickness Susceptibility · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06045481 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical Corps, Israel Defense Force
- Last refreshed: 13 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06045481.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing